Zykadia (ceritinib) by Novartis is approved for first line use in US

As of May 26, 2017 the FDA approved ceritinib for first line use. So it will go head to head with crizotinib. One article said a similar EU approval was likely “in coming weeks”.

The results are based on the phase 3 ASCEND-4 trial which found that in the first line setting that patients who took  ceritinib had a median progression-free survival of 16.6 months vs. 8.1 months on Pemetrexed platinum chemotherapy.

https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-expanded-use-zykadiar-first-line-alk-positive

 

This entry was posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research. Bookmark the permalink.

Leave a Reply